Jubilant Pharmova Limited — Board Meeting, 12-06-2025: Outcome of Board Meeting

Jubilant Pharmova has announced a board meeting on approving the transfer of its API business to Jubilant Biosys, its wholly owned subsidiary. The API segment, with Rs. 609 Cr turnover and Rs. 666.5 Cr net worth, accounts for over 8% of consolidated revenue. This move aims to unify drug discovery and API operations to enhance efficiency, brand value, and asset use. Payment will mainly be via share issuance. The company plans to double API revenues by 2030 and push EBITDA margins past 15% through new product launches and custom manufacturing.